M. Monroy-Iglesias, K. O'Connell, Jenna Bhimani, Victoria S Blinder, Rachael P Burganowski-Doud, I. Ergas, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Cecile A Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Janise M. Roh, Y. Sampathkumar, S. Tabatabai, E. Valice, Peng Wang, Erin J. Aiello Bowles, Elisa V. Bandera, L. Kushi, Elizabeth D. Kantor
2026.2.24CANCER
tlooto Summary
For most cytotoxic drugs, guidelines recommend body‐surface‐area–based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns, yet some patients start with reduced doses, potentially reflecting tolerability concerns.
Abstract
For most cytotoxic drugs, guidelines recommend body‐surface‐area–based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns. The relationship between first‐cycle dose reductions and subsequent delivery is unclear.
Citation format
MONROY-IGLESIAS, M., et al. Initial chemotherapy dose reductions and subsequent treatment delivery in early-stage breast cancer. CANCER, 2026, 132(5): e70294-e70294.